Clicky

Bristol-Myers Squibb Company(BMY) News

Date Title
Mar 15 FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Mar 15 Bristol Myers Squibb (BMY) Stock Moves -0.29%: What You Should Know
Mar 15 UPDATE 2-US FDA panel unanimously backs expanded use of J&J's CAR-T therapy
Mar 15 20 States with the Highest Cancer Rates
Mar 15 Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
Mar 15 Bristol Myers cell therapy wins first-of-its-kind approval
Mar 15 CORRECTED-UPDATE 2-US FDA expands use of Bristol Myers' cancer therapy (March 14)
Mar 15 U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Mar 14 Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Mar 13 UPDATE 3-US FDA staff raise concerns over data from J&J, Bristol's CAR-T therapies
Mar 13 Analysts on Wall Street Lower Ratings for These 10 Stocks
Mar 13 US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies
Mar 13 11 Oversold Healthcare Stocks To Buy Right Now
Mar 11 Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
Mar 11 15 Best ETFs To Buy Now
Mar 8 Bristol-Myers Squibb (NYSE:BMY) Will Pay A Dividend Of $0.60
Mar 7 Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
Mar 7 U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Mar 7 Amgen (AMGN) Down 6.5% Since Last Earnings Report: Can It Rebound?
Mar 6 Bristol Myers Squibb to Participate in Upcoming Investor Conferences